CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
We received an updated WNV package insert; please note the manufacturer and license number has been ...